Abstract
Background
Cancer outcome is considered to result from the interplay of several factors, among which host inflammatory and immune status are deemed to play a significant role. The neutrophil-to-lymphocyte ratio (NLR) and the lymphocyte-to-monocyte ratio (LMR) have been profitably used as surrogate markers of host immunoinflammatory status and have also been shown to correlate with outcome in several human tumors. However, only a few studies on these biomarkers have been performed in gastric cancer patients, yielding conflicting results.
Methods
Data were retrieved from a prospective institutional database. Overall survival (OS) of 401 patients undergoing surgery for gastric cancer between January 2000 and June 2015 as well as disease-free survival (DFS) rates in 297 radically resected patients were calculated. MaxStat analysis was used to select cutoff values for NLR and LMR.
Results
NLR and LMR did not significantly correlate with tumor stage. Patients with a high NLR and a low LMR experienced more tumor recurrences (p < 0.001) and had a higher hazard ratio (HR) for both OS (HR = 2.4 and HR = 2.10; p < 0.001) and DFS (HR = 2.99 and HR = 2.46; p < 0.001) than low NLR and high LMR subjects. Both biomarkers were shown to independently predict OS (HR = 1.65, p = 0.016; HR = 2.01, p = 0.002, respectively) and DFS (HR = 3.04, p = 0.019; HR = 4.76, p = 0.002, respectively). A score system combining both biomarkers was found to significantly correlate with long-term results.
Conclusions
A simple prognostic score including preoperative NLR and LMR can be used to easily predict outcome in gastric cancer patients undergoing surgery.
Similar content being viewed by others
References
Author names in bold designate shared co-first authorship
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—An Update. Cancer Epidemiol Biomarkers Prev 2016;25(1):16–27. doi: 10.1158/1055-9965.EPI-15-0578. Review.
Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014;20:1635–1649.
Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg 2016;263:326–336.
Liu X, Chen S, Liu J, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Impact of systemic inflammation on gastric cancer outcomes. PLoS One 2017;12(3):e0174085. doi:10.1371/journal.pone.0174085.eCollection
Feng F, Sun L, Zheng G, Liu S, Liu Z, Xu G, Guo M, Lian X, Fan D, Zhang H. Low lymphocyte-to-white blood cell ratio and high monocyte-to-white blood cell ratio predict poor prognosis in gastric cancer. Oncotarget 2017;8:5281–5291.
Lichtman MA. A Bacterial Cause of Cancer: An Historical Essay. Oncologist 2017. doi: 10.1634/theoncologist.2017-0007.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–444.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB, Khong HT. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget 2017. doi: 10.18632/oncotarget.16291.
Zhou XL, Li YQ, Zhu WG, Yu CH, Song YQ, Wang WW, He DC, Tao GZ, Tong YS. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Sci Rep 2017;7:42581. doi: 10.1038/srep42581.
Galizia G, Lieto E, Zamboli A, De Vita F, Castellano P, Romano C, et al. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery 2015;158:112–120.
Jiang N, Deng JY, Liu Y, Ke B, Liu HG, Liang H. The role of preoperative neutrophil-lymphocyte and platelet lymphocyte ratio in patients after radical resection for gastric cancer. Biomarkers 2014;19:444–451.
Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biology 2012;33:749–756.
Sun J, Chen X, Gao P, Song Y, Huang X, Yang Y, Zhao J, Ma B, Gao X, Wang Z. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. Dis Markers 2016;2016:7862469. doi: 10.1155/2016/7862469. Review.
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218:1402–1410.
Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer 2016;16:722–732.
Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z, Xu J. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer 2015;113:626–633.
Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 2017;265:539–546.
Zhou X, Du Y, Xu J, Huang Z, Qiu T, Wang X, Qian J, Zhu W, Liu P. The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage II/III gastric cancer. Tumour Biol 2014;35:11659–11666.
Deng Q, He B, Liu X, Yue J, Ying H, Pan Y, Sun H, Chen J, Wang F, Gao T, Zhang L, Wang S. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med 2015;13:66. doi: 10.1186/s12967-015-0409-0.
Hsu JT, Wang CC, Le PH, Chen TH, Kuo CJ, Lin CJ, Chou WC, Yeh TS. Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes. J Surg Res 2016;202:284–290.
Ajani JA, In H, Sano T, Gaspar LE, Erasmus JJ, Tang LH, et al. Stomach. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual. Eighth Ed. Springer, 2017:203–220.
Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg 2016;263:292–297.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet 2012;379: 315–321.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250:187–196.
Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: East versus west. J Surg Oncol 2017;115:603–614.
Mohri Y, Tanaka K, Toiyama Y, Ohi M, Yasuda H, Inoue Y, Kusunoki M. Impact of preoperative neutrophil to lymphocyte ratio and postoperative infectious complications on survival after curative gastrectomy for gastric cancer: A single institutional cohort study. Medicine (Baltimore) 2016;95(11):e3125. doi: 10.1097/MD.0000000000003125.
Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, Bridgewater J. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol 2016;27:687–692.
Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, Oh DY. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer 2017;20:254–262.
Borda A, Vila J, Fernández-Urién I, Zozaya JM, Guerra A, Borda F. Pretreatment predictive value of blood neutrophil/lymphocyte ratio in R0 gastric cancer resectability. Gastroenterol Hepatol 2017;40:1–9.
Chan YH. Biostatistics 203. Survival Analysis. Singapore Med J 2004;45:249–256.
Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130:515–524.
Lönnroth C, Andersson M, Asting AG, Nordgren S, Lundholm K. Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int J Oncol 2014;45:2208–20.
Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 2009;12:6–22.
Author information
Authors and Affiliations
Contributions
E. Lieto, G. Galizia, M. Orditura, and V. Napolitano made a substantial contribution to the concept and design; A. Auricchio, F. Cardella, A. Mabilia, N. Basile, G. Del Sorbo, and P. Castellano collected the data; E. Lieto, G. Galizia, and C. Romano interpreted the data; G. Galizia and M. Orditura performed the statistical analysis; E. Lieto, G. Galizia, C. Romano, M. Orditura, and V. Napolitano drafted the manuscript; A. Auricchio, F: Cardella, A. Mabilia, N. Basile, G. Del Sorbo, and P. Castellano revised the manuscript critically for important intellectual content; all authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
No Grant Support
The paper was not presented at any scientific meeting.
Rights and permissions
About this article
Cite this article
Lieto, E., Galizia, G., Auricchio, A. et al. Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. J Gastrointest Surg 21, 1764–1774 (2017). https://doi.org/10.1007/s11605-017-3515-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-017-3515-x